Download PDF
Hamostaseologie 2010; 30(S 01): S54-S55
DOI: 10.1055/s-0037-1619073
Communication
Schattauer GmbH

Sequential combined bypassing therapy of bleeds unresponsive to a single bypassing agent

Safety and efficacyKombinierte Sequenztherapie mit BypassingProdukten zur Therapie von Blutungen, die nicht mit einem einzigen Bypassing-Produkt beherrscht werden könnenSicherheit und Wirksamkeit
R. Klamroth
1   Hämophiliezentrum, Vivantes – Klinikum im Friedrichshain, Berlin
,
K. Holstein
2   Klinik für Innere Medizin, Hämatologie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Germany
,
M. von Depka
3   Werlhof-Institut, Hannover, Germany
,
A. Gringeri
4   Bianchi Bonomi Hemophilia & Thrombosis Center, Mailand, Italy
,
K. Fischer
5   Van Creveldkliniek, Department of Haematology, University Medical Center, Utrecht, Netherlands
,
A. Karafoulidou
6   2nd Blood Transfusion Center and Hemophilia Center, Laikon General Hospital, Athens, Greece
,
M. F. Lopez-Fernandez
7   Servicio de Hematología y Hemotherapia, Complexo Hospitalario Juan Canalejo, A Coruña, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
23 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-248.
    CrossrefPubMedGoogle Scholar